The anti-inflammatory effects of nebivolol in human coronary smooth muscle cells: Clinical implications
International Journal of Cardiology, ISSN: 0167-5273, Vol: 133, Issue: 3, Page: 415-416
2009
- 8Citations
- 17Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Given that the majority of hypertensives require more than one drug to control blood pressure, the pleitropic effects (especially anti-inflammatory effects) and favourable metabolic profile of nebivolol could make it an alternative drug regimen for hypertensives requiring beta-blocker treatment. Although standard beta-blockers seem to have a hard time at present, we are convinced that perhaps the new generation beta-blockers such as nebivolol might yet ‘rescue’ the reputation of beta blockers in the near-future.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0167527307021341; http://dx.doi.org/10.1016/j.ijcard.2007.11.095; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=63149124997&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/18237789; https://linkinghub.elsevier.com/retrieve/pii/S0167527307021341
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know